We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

124 hedge funds and large institutions have $440M invested in Immunomedics Inc in 2017 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

99% more capital invested

Capital invested by funds: $221M → $440M (+$219M)

86% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $11.4M

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

14% more funds holding

Funds holding: 109124 (+15)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
124
Holders Change
+15
Holders Change %
+13.76%
% of All Funds
3.09%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
36
Increased
39
Reduced
32
Closed
15
Calls
$21.2M
Puts
$11.4M
Net Calls
+$9.85M
Net Calls Change
+$622K
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$67.9M +$6.2M +1,224,736 +13%
BlackRock
2
BlackRock
New York
$51.2M +$40.1M +7,907,956 +92,632%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$30.4M +$23.2M +4,570,042 +3,633%
Vanguard Group
4
Vanguard Group
Pennsylvania
$28.6M +$2.37M +468,314 +12%
FCM
5
Farallon Capital Management
California
$26.9M +$21M +4,155,000 New
State Street
6
State Street
Massachusetts
$22.7M +$9.64M +1,903,355 +118%
RG
7
Redmile Group
California
$21.9M +$17.1M +3,380,846 New
FLAM
8
First Light Asset Management
Minnesota
$13.6M -$940K -185,514 -8%
Millennium Management
9
Millennium Management
New York
$11.6M -$5.26M -1,038,857 -37%
ACH
10
ArrowMark Colorado Holdings
Colorado
$10.6M +$594K +117,214 +8%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$9.86M +$1.98M +391,815 +35%
GTC
12
Ghost Tree Capital
New York
$9.71M -$1.01M -200,000 -12%
Northern Trust
13
Northern Trust
Illinois
$8.06M +$323K +63,786 +5%
O
14
OrbiMed
New York
$7.97M -$13M -2,569,900 -68%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$7.74M +$5.71M +1,127,213 +1,648%
OM
16
Opaleye Management
Massachusetts
$6.21M +$4.86M +960,000 New
SFM
17
Sphera Funds Management
Israel
$6.15M -$507K -100,000 -10%
Adage Capital Partners
18
Adage Capital Partners
Massachusetts
$6.15M +$4.81M +950,000 New
6CM
19
683 Capital Management
New York
$5.34M +$1.27M +250,000 +43%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$5.2M +$495K +97,640 +14%
PVI
21
Pura Vida Investments
New York
$3.53M +$1.06M +208,500 +62%
CS
22
Candriam SCA
Luxembourg
$3.3M +$2.58M +510,000 New
ACP
23
Acuta Capital Partners
California
$3.25M -$21.3M -4,197,000 -89%
RPAM
24
Rhenman & Partners Asset Management
Sweden
$3.1M +$2.43M +479,610 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$3M +$119K +23,518 +5%

IMMU Hedge Fund Activity: Q1 2017 in Review

124 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2017, worth a combined $440M — up 99% from $221M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new IMMU positions and 15 closed out — a net gain of 21 holders — while 39 added to existing stakes and 32 trimmed.

The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Acuta Capital Partners, cutting an estimated $21.3M.

  • 124 institutional investors held Immunomedics Inc (IMMU) as of Q1 2017, up from 109 in Q4 2016.
  • Funds reported $440M of Immunomedics Inc stock for Q1 2017, up 99% quarter-over-quarter.
  • 36 funds opened new Immunomedics Inc positions in Q1 2017 and 15 closed out, a net change of +21 holders.
  • The largest Immunomedics Inc buyer in Q1 2017 was BlackRock, an estimated $40.1M added.
  • The largest Immunomedics Inc seller in Q1 2017 was Acuta Capital Partners, an estimated $21.3M sold.

Based on aggregated 13F filings for Q1 2017.